Etrolizumab (Anti-Integrin a4b7) (ITGA4 & ITGB7)
Etrolizumab (Anti-Integrin a4b7) (ITGA4 & ITGB7) is a gut‐selective humanized monoclonal antibody targets β7 integrins with a potential to treat inflammatory bowel disease (IBD). MW: 144.3 KD.
Supplier | Selleck Chemicals |
---|---|
Product # | A2856 |
Sku # | A2856-1mg |
Pricing | 1mg, $570.00 |